IMRT for Prostate Cancer: Comparing Toxicity with and without Pelvic Lymph Node Treatment
Author Information
Author(s): Guckenberger Matthias, Baier Kurt, Richter Anne, Vordermark Dirk, Flentje Michael
Primary Institution: Department of Radiation Oncology, Julius-Maximilians University, Wuerzburg, Germany
Hypothesis
Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Conclusion
The study found that treating the pelvic lymph nodes does not significantly increase the risk of rectal, bladder, or small bowel toxicity compared to treating the prostate alone.
Supporting Evidence
- NTCP for late rectal toxicity ranged between 5% and 8% with no significant difference between treatment plans.
- NTCP for late bladder toxicity was less than 1% for both treatment plans.
- The risk of small bowel toxicity was moderately increased for the plan treating pelvic lymph nodes.
Takeaway
Doctors wanted to see if treating more areas around the prostate with radiation would hurt patients more. They found it didn't really make things worse.
Methodology
This was a retrospective planning study involving ten patients with localized prostate cancer, comparing IMRT plans for prostate-only treatment and additional pelvic lymph node treatment.
Potential Biases
The study may be limited by the small sample size and the retrospective nature of the analysis.
Limitations
The study's calculations were based on a single planning CT study, which may not represent variability in patient anatomy during treatment.
Participant Demographics
Ten consecutive patients treated for localized prostate cancer at the Department of Radiation Oncology of the University of Wuerzburg, Germany.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website